Bank of New York Mellon Corp Increases Stake in Immunome, Inc. (NASDAQ:IMNM)

Bank of New York Mellon Corp boosted its position in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 56.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 193,147 shares of the company's stock after purchasing an additional 69,944 shares during the period. Bank of New York Mellon Corp owned about 0.22% of Immunome worth $1,300,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. BNP Paribas Financial Markets purchased a new stake in shares of Immunome during the 4th quarter valued at approximately $70,000. KLP Kapitalforvaltning AS bought a new stake in Immunome during the 4th quarter valued at $75,000. Tower Research Capital LLC TRC lifted its position in shares of Immunome by 482.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock worth $91,000 after acquiring an additional 7,129 shares in the last quarter. Aquatic Capital Management LLC purchased a new stake in shares of Immunome during the fourth quarter worth $95,000. Finally, Teacher Retirement System of Texas boosted its holdings in shares of Immunome by 49.0% in the first quarter. Teacher Retirement System of Texas now owns 17,360 shares of the company's stock worth $117,000 after acquiring an additional 5,712 shares during the period. 44.58% of the stock is owned by institutional investors.

Immunome Price Performance

NASDAQ IMNM traded up $0.07 during trading on Friday, reaching $10.59. The company's stock had a trading volume of 632,439 shares, compared to its average volume of 870,397. The firm has a fifty day moving average of $9.34 and a 200 day moving average of $8.90. Immunome, Inc. has a one year low of $5.15 and a one year high of $16.73.

Immunome (NASDAQ:IMNM - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.14. Immunome had a negative net margin of 1,875.21% and a negative return on equity of 71.65%. The company had revenue of $2.93 million for the quarter, compared to analysts' expectations of $0.46 million. As a group, equities analysts anticipate that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Insider Buying and Selling at Immunome

In related news, Director Jean Jacques Bienaime acquired 5,000 shares of the company's stock in a transaction dated Tuesday, June 3rd. The stock was bought at an average cost of $9.38 per share, with a total value of $46,900.00. Following the acquisition, the director owned 36,415 shares of the company's stock, valued at approximately $341,572.70. The trade was a 15.92% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 8.60% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Wall Street Zen upgraded Immunome from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Wedbush reiterated an "outperform" rating and set a $21.00 price target (down from $33.00) on shares of Immunome in a research report on Tuesday, May 13th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Immunome currently has a consensus rating of "Moderate Buy" and an average price target of $23.33.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.